Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ANEB

Anebulo Pharmaceuticals (ANEB)

Anebulo Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ANEB
DateTimeSourceHeadlineSymbolCompany
06/17/20243:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/17/20243:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/17/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
05/15/20243:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
05/15/20243:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
05/15/202412:05PMBusiness WireAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
02/13/20243:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
02/13/20243:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
02/13/20243:05PMBusiness WireAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/21/20233:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/14/20233:05PMBusiness WireAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/30/20238:31AMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/30/20238:22AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/19/20234:18PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/06/20233:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/06/20233:06PMBusiness WireAnebulo Pharmaceuticals Announces New CEONASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/06/20233:06PMBusiness WireAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/02/20234:01PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
09/22/20233:05PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
09/20/20233:29PMBusiness WireAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
09/20/20233:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
09/05/20237:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
08/30/20237:00AMBusiness WireAnebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
08/21/20237:00AMBusiness WireAnebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionNASDAQ:ANEBAnebulo Pharmaceuticals Inc
05/11/20233:07PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
05/11/20237:16AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
05/11/20237:00AMPR Newswire (US)Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
04/04/20235:33PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
03/28/20237:02AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
03/28/20237:00AMPR Newswire (US)Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid IntoxicationNASDAQ:ANEBAnebulo Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ANEB